A Phase 1 interventional study of Recombinant Vaccinia GM-CSF; RAC VAC GM-CSF (JX-594) in Carcinoma, Colorectal, sponsored by Jennerex Biotherapeutics. Completed at 1 site in South Korea. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-08.
Sponsored by Jennerex Biotherapeutics · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 283 studies in Colorectal Neoplasms with a site in Korea, Republic of — 60 open to participants now, 95 under way, 13 of them phase 3. Colorectal Neoplasms · Korea, Republic of.
Among the 283 studies in Colorectal Neoplasms with a site in Korea, Republic of, this one is the 240th largest by enrollment of the 251 interventional ones that give a count, is one of 12 that started in 2010, is one of 53 in phase 1, and was the 49th registered.
6,556 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.
Browse Colorectal Neoplasms studies →60 of the 283 studies in Colorectal Neoplasms with a site in Korea, Republic of are open now. Recruiting first, the newest first:
SK Life Science, Inc. · Sites in Korea, Republic of, United States
Ages 18+
AbbVie · Sites in Korea, Republic of, United States, Belgium and 8 more countries
Ages 18+
Gilead Sciences · Sites in Korea, Republic of, United States, Australia and 1 more country
Ages 18+
EMD Serono Research & Development Institute, Inc. · Sites in Korea, Republic of, United States, Argentina and 16 more countries
Ages 18+
Incyte Corporation · Sites in Korea, Republic of, United States, Argentina and 19 more countries
Ages 18+
A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →
Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
283 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 95 · Phase 2 102 · Phase 3 50 · Phase 4 4
First in 1991; this study’s year is marked. 12 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 15 is below the median of 76 across 4,811 interventional studies indexed under Colorectal Neoplasms.
Median enrollment 150 across the 251 interventional studies, 682 across the 32 observational. Of the 154 that completed or were terminated, 58 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
171 of 283 have an industry lead sponsor. The 10 most frequent:
Jennerex Biotherapeutics is the lead sponsor of 11 studies on the registry; none are open to participants now.
Jennerex Biotherapeutics has 3 studies filed under Colorectal Neoplasms — fewer than ten, so there is no comparison to draw.
26 of the studies in Colorectal Neoplasms with a site in Korea, Republic of that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05093907BeyondBio Inc.A Study to Evaluate Safety and Efficacy of BEY1107 in Combination with Capecitabine in Patients with Metastatic Colorectal Cancer | 2026-11-30 |
| NCT05784688TiumBio Co., Ltd.Study of TU2218 in Combination With KEYTRUDA®(Pembrolizumab) in Patients With Advanced Solid Tumors | 2026-12 |
| NCT04585750PMV Pharmaceuticals, IncThe Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) | 2026-12-15 |
| NCT06769087Seoul St. Mary's HospitalComparing Immediate Removal and Postoperative 1 Day of Urinary Catheter After Colorectal Cancer Surgery | 2026-12-31 |
| NCT07380867Seoul St. Mary's HospitalConfirming the Accuracy of Endoscopic Marking Using a New Marker, a Novel Luminomarker, in Lesion Marking Before Colorectal Cancer Surgery. | 2026-12-31 |
Add all 26 to your calendar (.ics) → With an account.
Among the 283 studies in Colorectal Neoplasms with a site in Korea, Republic of, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this pilot safety study is to evaluate the safety and tolerability of JX-594 (Pexa-Vec) administered intravenously every 2 weeks in colorectal carcinoma patients who are refractory to or intolerant of oxaliplatin, irinotecan, and Erbitux treatments.
This is a Phase Ib, open-label, dose-escalation study designed to evaluate the safety and tolerability of Pexa-Vec (JX-594), a vaccinia GM-CSF/thymidine kinase-deactivated virus, administered intravenously in patients with advanced/metastatic colorectal carcinoma (CRC) that is refractory to standard therapy. Vaccinia virus, from which Pexa-Vec is derived, shows a natural selectivity toward cancer relative to normal tissues after intravenous (IV) administration.
The study utilizes a sequential dose-escalating design to determine the maximum tolerated dose (MTD) and/or maximum feasible dose (MFD). Patients will receive 4 biweekly treatments of Pexa-Vec administered by IV infusion over 60 minutes on Days 1, 15, 29, and 43. Patients will be sequentially enrolled into one of three dose cohorts:
In addition to safety endpoints, secondary objectives include the evaluation of Pexa-Vec pharmacokinetics (PK), pharmacodynamics, immune response, and preliminary anti-tumoral activity. Tumor response assessments will be conducted using CT or MRI on Days 29 and 57 (±2 days) based on Response Evaluation Criteria in Solid Tumors (RECIST).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Dose escalation 1e6 pfu/kg bw, 1e7 pfu/kg bw, 3e7 pfu/kg bw of Recombinant Vaccinia GM-CSF JX-594
Drug: Recombinant Vaccinia GM-CSF; RAC VAC GM-CSF (JX-594)
Intravenous Dose Range: 1x10\^6 pfu/kg, 1x10\^7 pfu/kg, 3x10\^7 pfu/kg Up to 4 intravenous infusions administered over 60 minutes every 2 weeks.
Also known as: JX-594
Number of Participants Experiencing Dose-Limiting Toxicities (DLTs)
A DLT is defined as any of the following treatment-related adverse events: Grade 4 toxicity, Grade 3 hematologic toxicity for \> 5 days, or Grade 3 non-hematologic toxicities persisting for \> 7 days except for flu-like symptoms that respond to standard therapies. The number of participants with DLTs was used to determine the Maximally-Tolerated Dose (MTD) and/or Maximum-Feasible Dose (MFD) of JX-594.
Time frame: Up to Day 57 (assessed through 14 days following the 4th and final biweekly JX-594 infusion, an average of 8 weeks).
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
Adverse events were collected and assessed to evaluate safety and tolerability. A Treatment-Emergent Adverse Event (TEAE) is defined as an event with a start date on or after the date of the first dose of study treatment, or an event present at baseline that worsened in severity after the first dose.
Time frame: Up to Day 71 (assessed through 28 days following the 4th and final biweekly JX-594 infusion, an average of 10 weeks).
Number of Participants in Each Best Overall Tumor Response Category Based on RECIST
Anti-tumoral response was evaluated using Response Evaluation Criteria in Solid Tumors (RECIST) on CT or MRI. Categories include: Complete Response (CR) = Disappearance of all target lesions; Partial Response (PR) = \>=30% decrease in the sum of the longest diameters of target lesions; Progressive Disease (PD) = \>=20% increase in the sum of the longest diameters of target lesions or appearance of new lesions; Stable Disease (SD) = Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD.
Time frame: Up to Day 57 (Week 8)
Overall Survival (OS)
Overall survival (OS) was defined as the time from the first dose of Pexa-Vec until death from any cause. For patients not known to have died at the time of the analysis, OS was censored on the date they were last known to be alive.
Time frame: From the first dose of Pexa-Vec until death from any cause, assessed up to 24 months
Patients with metastatic, refractory colorectal carcinoma who had failed both oxaliplatin- and irinotecan-based prior chemotherapy regimens were recruited at a single study site (Samsung Medical Center) in Seoul, Republic of Korea. The recruitment and study conduct took place between September 08, 2010, and October 18, 2012
| Milestone | Cohort 1: Pexa-Vec 1 × 10^6 Pfu/kg | Cohort 2: Pexa-Vec 1 × 10^7 Pfu/kg | Cohort 3: Pexa-Vec 3 × 10^7 Pfu/kg |
|---|---|---|---|
| Started | 3 | 3 | 9 |
| Completed | 2 | 2 | 7 |
| Not completed | 1 | 1 | 2 |
A DLT is defined as any of the following treatment-related adverse events: Grade 4 toxicity, Grade 3 hematologic toxicity for \> 5 days, or Grade 3 non-hematologic toxicities persisting for \> 7 days except for flu-like symptoms that respond to standard therapies. The number of participants with DLTs was used to determine the Maximally-Tolerated Dose (MTD) and/or Maximum-Feasible Dose (MFD) of JX-594.
| Participants | Cohort 1: Pexa-Vec 1 × 10^6 Pfu/kg | Cohort 2: Pexa-Vec 1 × 10^7 Pfu/kg | Cohort 3: Pexa-Vec 3 × 10^7 Pfu/kg |
|---|---|---|---|
| Number of Participants Experiencing Dose-Limiting Toxicities (DLTs) | 0 | 0 | 0 |
Adverse events were collected and assessed to evaluate safety and tolerability. A Treatment-Emergent Adverse Event (TEAE) is defined as an event with a start date on or after the date of the first dose of study treatment, or an event present at baseline that worsened in severity after the first dose.
| Participants | Cohort 1: Pexa-Vec 1 × 10^6 Pfu/kg | Cohort 2: Pexa-Vec 1 × 10^7 Pfu/kg | Cohort 3: Pexa-Vec 3 × 10^7 Pfu/kg |
|---|---|---|---|
| Experienced TEAE | 3 | 3 | 9 |
| Did NOT Experience TEAE | 0 | 0 | 0 |
Anti-tumoral response was evaluated using Response Evaluation Criteria in Solid Tumors (RECIST) on CT or MRI. Categories include: Complete Response (CR) = Disappearance of all target lesions; Partial Response (PR) = \>=30% decrease in the sum of the longest diameters of target lesions; Progressive Disease (PD) = \>=20% increase in the sum of the longest diameters of target lesions or appearance of new lesions; Stable Disease (SD) = Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD.
| Participants | Cohort 1: Pexa-Vec 1 × 10^6 Pfu/kg | Cohort 2: Pexa-Vec 1 × 10^7 Pfu/kg | Cohort 3: Pexa-Vec 3 × 10^7 Pfu/kg |
|---|---|---|---|
| Complete Response | 0 | 0 | 0 |
| Partial Response | 0 | 0 | 0 |
| Stable Disease | 0 | 2 | 5 |
| Progressive Disease | 2 | 0 | 2 |
| No Post-Baseline Assessment | 1 | 1 | 2 |
Overall survival (OS) was defined as the time from the first dose of Pexa-Vec until death from any cause. For patients not known to have died at the time of the analysis, OS was censored on the date they were last known to be alive.
| months | Cohort 1: Pexa-Vec 1 × 10^6 Pfu/kg | Cohort 2: Pexa-Vec 1 × 10^7 Pfu/kg | Cohort 3: Pexa-Vec 3 × 10^7 Pfu/kg |
|---|---|---|---|
| Overall Survival (OS) | 10.4 (10.19 to 10.61) | 5.06 (NA to NA) | 10.22 (5.06 to 11.43) |
Collected over Up to approximately 24 months (from the first dose until study completion). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort 1: Pexa-Vec 1 × 10^6 Pfu/kg | 2/3 (66.7%) | 0/3 (0%) | 3/3 (100%) |
| Cohort 2: Pexa-Vec 1 × 10^7 Pfu/kg | 1/3 (33.3%) | 0/3 (0%) | 3/3 (100%) |
| Cohort 3: Pexa-Vec 3 × 10^7 Pfu/kg | 5/9 (55.6%) | 2/9 (22.2%) | 9/9 (100%) |
| Event | Cohort 1: Pexa-Vec 1 × 10^6 Pfu/kg | Cohort 2: Pexa-Vec 1 × 10^7 Pfu/kg | Cohort 3: Pexa-Vec 3 × 10^7 Pfu/kg |
|---|---|---|---|
| Pneumonia necrotisingInfections and infestations | 0/3 | 0/3 | 1/9 |
| Disease progressionGeneral disorders | 0/3 | 0/3 | 1/9 |
| Event | Cohort 1: Pexa-Vec 1 × 10^6 Pfu/kg | Cohort 2: Pexa-Vec 1 × 10^7 Pfu/kg | Cohort 3: Pexa-Vec 3 × 10^7 Pfu/kg |
|---|---|---|---|
| PyrexiaGeneral disorders | 3/3 | 3/3 | 8/9 |
| ChillsGeneral disorders | 1/3 | 3/3 | 9/9 |
| NauseaGastrointestinal disorders | 3/3 | 2/3 | 4/9 |
| HeadacheNervous system disorders | 2/3 | 3/3 | 4/9 |
| Rash pustularInfections and infestations | 0/3 | 0/3 | 7/9 |
| HypotensionVascular disorders | 1/3 | 1/3 | 4/9 |
| FatigueGeneral disorders | 1/3 | 1/3 | 1/9 |
| VomitingGastrointestinal disorders | 1/3 | 0/3 | 3/9 |
| StomatitisGastrointestinal disorders | 0/3 | 1/3 | 2/9 |
| DiarrhoeaGastrointestinal disorders | 1/3 | 1/3 | 1/9 |
The baseline analysis population is based on the Intent-to-Treat (ITT) population, which includes all enrolled patients who received at least one treatment of Pexa-Vec
| Age, Continuous(Years) | Cohort 1: Pexa-Vec 1 × 10^6 Pfu/kg | Cohort 2: Pexa-Vec 1 × 10^7 Pfu/kg | Cohort 3: Pexa-Vec 3 × 10^7 Pfu/kg | Total |
|---|---|---|---|---|
| Mean | 46 ± 13.45 | 56.3 ± 10.97 | 56.7 ± 13.15 | 54.5 ± 12.69 |
| Sex: Female, Male(Participants) | Cohort 1: Pexa-Vec 1 × 10^6 Pfu/kg | Cohort 2: Pexa-Vec 1 × 10^7 Pfu/kg | Cohort 3: Pexa-Vec 3 × 10^7 Pfu/kg | Total |
|---|---|---|---|---|
| Female | 2 | 2 | 1 | 5 |
| Male | 1 | 1 | 8 | 10 |
| Race (NIH/OMB)(Participants) | Cohort 1: Pexa-Vec 1 × 10^6 Pfu/kg | Cohort 2: Pexa-Vec 1 × 10^7 Pfu/kg | Cohort 3: Pexa-Vec 3 × 10^7 Pfu/kg | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 3 | 3 | 9 | 15 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 |
| White | 0 | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Region of Enrollment(Participants) | Cohort 1: Pexa-Vec 1 × 10^6 Pfu/kg | Cohort 2: Pexa-Vec 1 × 10^7 Pfu/kg | Cohort 3: Pexa-Vec 3 × 10^7 Pfu/kg | Total |
|---|---|---|---|---|
| South Korea | 3 | 3 | 9 | 15 |
| American Joint Committee on Cancer (AJCC) Staging(Participants) | Cohort 1: Pexa-Vec 1 × 10^6 Pfu/kg | Cohort 2: Pexa-Vec 1 × 10^7 Pfu/kg | Cohort 3: Pexa-Vec 3 × 10^7 Pfu/kg | Total |
|---|---|---|---|---|
| Stage IVA | 2 | 0 | 0 | 2 |
| Stage IVB | 1 | 3 | 9 | 13 |
| KRAS Mutational Status(Participants) | Cohort 1: Pexa-Vec 1 × 10^6 Pfu/kg | Cohort 2: Pexa-Vec 1 × 10^7 Pfu/kg | Cohort 3: Pexa-Vec 3 × 10^7 Pfu/kg | Total |
|---|---|---|---|---|
| Wild-type | 2 | 1 | 8 | 11 |
| Mutant | 1 | 1 | 1 | 3 |
| Not Assessed | 0 | 1 | 0 | 1 |
| Received Smallpox Vaccine(Participants) | Cohort 1: Pexa-Vec 1 × 10^6 Pfu/kg | Cohort 2: Pexa-Vec 1 × 10^7 Pfu/kg | Cohort 3: Pexa-Vec 3 × 10^7 Pfu/kg | Total |
|---|---|---|---|---|
| Yes | 2 | 1 | 1 | 4 |
| No | 0 | 1 | 2 | 3 |
| Unknown | 1 | 1 | 6 | 8 |
The record gives a start of Sep 2010, a primary completion of Oct 2012 and a completion of Oct 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2026, 13 years 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: JX-594
Jennerex Biotherapeutics